CHAPTER 6: D₃ Receptor Agonists and Antagonists as Anti‐Parkinsonian Therapeutic Agents Check Access

Since its discovery, the dopamine D₃ receptor has become an important therapeutic target for the development of drugs for neuropsychiatric disorders and Parkinson’s disease. Consequently, an enormous amount of effort has been directed towards development of D₃ receptor‐selective molecules. Here we present a comprehensive review on drug development directed towards D₃ receptors for the treatment of Parkinson’s disease. D₃ receptor‐selective molecules belonging to both agonist and antagonist classes are included. Furthermore, the potential of D₃ receptors as neuroprotective targets, as well as their role in the development and treatment of L‐DOPA‐induced dyskinesia, is also covered.